{"disease":{"id":"pd-1-immunotherapy","name":"pd 1 immunotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05468138","title":"PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":141,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06903858","title":"Neoadjuvant Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07359040","title":"Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05265793","title":"Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06262581","title":"Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06288360","title":"Neoadjuvant Immunochemotherapy in PD-L1-negative LACC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04815408","title":"PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04188860","title":"Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Lei Li","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}